Ardena, a contract development and manufacturing organisation (CDMO), has acquired Syntagon, a contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.
Acquisition
This acquisition represents the first for Ardena that falls outside of the Benelux region and will see the company expand its drug substance manufacturing capacity to now enable the handling of batches of up to 100 kg. Additionally, the acquisition of Syntagon will add specialist expertise in GMP chromatographic purification processes to the group.
This latest announcement follows the company’s acquisition of ChemConnection earlier this year (March 2018) and forms part of the strategy to become a leading integrated drug development company and reach €35 million sales mark.
“At Ardena, it is our goal to become a one source contractor by offering an integrated set of services to meet all chemical, pharmaceutical and (bio)analytical needs that arise in the clinical supply chain from lab to patient. This is the driver of our M&A strategy,” stated Harry Christiaens, CEO of Ardena. “By adding the ChemConnection and Syntagon capabilities to our group, we can now offer specialist technology expertise in drug substance manufacturing.
“The Syntagon acquisition gives us a presence in Scandinavia, where we are well positioned to capitalise on the emerging biotech segment and broader pharmaceutical market. With support from our financial investor Mentha Capital, we will continue to focus on both organic growth and acquisition opportunities on our path to create an internationally recognised drug development company.”
Commenting on the acquisition, Michael Lofthagen, CEO at Syntagon added: “Our customers can now benefit from a more integrated service offering, which will ultimately streamline the progress of products through clinical development. We are looking forward to leveraging the synergies across the Ardena group to deliver the best possible offering to the market.”